Hostname: page-component-7479d7b7d-qlrfm Total loading time: 0 Render date: 2024-07-09T15:46:56.514Z Has data issue: false hasContentIssue false

Depression in patients with coronary heart disease

Published online by Cambridge University Press:  16 April 2020

A. Baloescu
Affiliation:
Department of Psychiatry, Central Military Hospital, Bucharest, Romania
G. Grigorescu
Affiliation:
Department of Psychiatry, Central Military Hospital, Bucharest, Romania
M. Miclos
Affiliation:
Department of Psychiatry, Central Military Hospital, Bucharest, Romania
E. Badescu
Affiliation:
Department of Psychiatry, Central Military Hospital, Bucharest, Romania
M.D. Gheorghe
Affiliation:
Department of Psychiatry, Central Military Hospital, Bucharest, Romania

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

Depression is a risk factor for coronary heart disease (CHD) and for other cardiovascular diseases. It cause high mortality in known patients. SSRIs are safe and have a negligible effect on the cardiovascular system, even in cases of overdose.

Objective:

To examine the antidepressant effect of sertraline and paroxetine in patients with CHD after the incidence of an acute coronary event.

Method:

46 patients (26 female, mean age 59,8; 20 male, mean age 57,8) diagnosed with CHD, after 1-3 months from an acute coronary syndrome, no depression in the past, met the criteria for major depressive disorder (MDD) according to ICD10. It was performed HAMD 17 items.

Results:

Patients received either sertraline 75-150 mg/day (n=23; mean dose 104,3 mg/day) or paroxetine 20-30 mg/day (n=23; mean dose 22,6 mg/day). They were examined on baseline and days 7, 28, 56, 112, 168 using cardiologic evaluation, and depression rating scale HAMD. All treated patients had a significant improvement on HAMD score (from mean 21,8 to 10,6). Significant improvement was noted at 28 days of treatment. 12/46 (26,08%) were mildly improved and 34/46 (73,92%) were much or very much improved. No important side effects were recorded.

Conclusions:

1) Patients with no recent history of depression suffering a cardiovascular event were more likely to be diagnosed with depression. 2) Diagnosis and treatment of depression should be incorporated into the clinical management of CHD 3) Sertraline and paroxetine are a safe and effective treatment in patients with CHD without other life-threatening medical conditions.

Type
Poster Session 1: Schizophrenia and Other Psychosis
Copyright
Copyright © European Psychiatric Association 2007
Submit a response

Comments

No Comments have been published for this article.